Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline-filled breast implant sizers to identify the correct style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SIEN
CUSIPN/A
Phone805-562-3500
Debt
Debt-to-Equity Ratio2.31
Current Ratio1.21
Quick Ratio0.71
Price-To-Earnings
Trailing P/E Ratio-7.16
Forward P/E Ratio-7.65
P/E GrowthN/A
Sales & Book Value
Annual Sales$36.54 million
Price / Sales15.58
Cash FlowN/A
Price / CashN/A
Book Value$1.42 per share
Price / Book14.23
Profitability
EPS (Most Recent Fiscal Year)($2.82)
Net Income$-64,020,000.00
Net Margins-164.72%
Return on Equity-181.25%
Return on Assets-65.09%
Miscellaneous
Employees200
Outstanding Shares28,180,000
Sientra (NASDAQ:SIEN) Frequently Asked Questions
What is Sientra's stock symbol?
Sientra trades on the NASDAQ under the ticker symbol "SIEN."
How were Sientra's earnings last quarter?
Sientra (NASDAQ:SIEN) released its quarterly earnings data on Wednesday, May, 9th. The medical instruments supplier reported ($0.99) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.84) by $0.15. The medical instruments supplier earned $14.60 million during the quarter, compared to analysts' expectations of $14.49 million. Sientra had a negative return on equity of 181.25% and a negative net margin of 164.72%. The firm's quarterly revenue was up 95.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.61 EPS. View Sientra's Earnings History.
What price target have analysts set for SIEN?
8 Wall Street analysts have issued 1-year target prices for Sientra's stock. Their predictions range from $12.00 to $23.00. On average, they anticipate Sientra's stock price to reach $17.1667 in the next year. View Analyst Ratings for Sientra.
What are Wall Street analysts saying about Sientra stock?
Here are some recent quotes from research analysts about Sientra stock:
- 1. Maxim Group analysts commented, "SIEN has had a strong start to 2018. It received approval of its Vesta facility in April, launched its rebranded breast implants, reported a strong first quarter for its MiraDry system, and added an additional $117.7M in combined equity and debt financing in May. Although we remain optimistic in SIEN’s long-term opportunities, the valuation is significantly ahead of peer averages and the stock price has exceeded our 12-month target. As a result, we are downgrading our rating to and removing our $19 price target." (6/8/2018)
- 2. According to Zacks Investment Research, "Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra's primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. " (6/7/2018)
- 3. Canaccord Genuity analysts commented, "We reiterate our BUY rating on Sientra following strong Q1/18 results that came in slightly ahead of prelim results. SIEN has had a busy start to the year executing on key initiatives that leave us incrementally more confident in the company’s ability to deliver upside to estimates moving forward. Specifically, SIEN received FDA approval of the company’s new manufacturing facility and immediately re-entered the US breast implant market early in the Q2, posted a robust Q1 that showed continued momentum in tissue expander sales as well as encouraging signs of a turnaround in the miraDry business, and lastly completed a $108M (net of fees) capital raise." (5/10/2018)
Who are some of Sientra's key competitors?
Some companies that are related to Sientra include Invacare (IVC), Consort Medical (CSRMY), RTI Surgical (RTIX), Lakeland Industries (LAKE), Histogenics (HSGX), ConforMIS (CFMS), Rewalk Robotics (RWLK), NanoVibronix (NAOV), Precision Therapeutics (AIPT), Allied Healthcare Products (AHPI), Bionik Laboratories (BNKL) and Avitar (AVTI).
Who are Sientra's key executives?
Sientra's management team includes the folowing people:
- Mr. Jeffrey M. Nugent, Chairman & CEO (Age 71)
- Mr. Patrick F. Williams, CFO, Sr. VP, Principal Accounting Officer & Treasurer (Age 45)
- Mr. Charles Huiner, Chief Operating Officer and Sr. VP of Corp. Devel. & Strategy (Age 47)
- Ms. Deborah Bettencourt, VP of Customer Experience & Corp. Admin.
- Mr. Jason O'Hearn, VP of Sales & Professional Relations
Has Sientra been receiving favorable news coverage?
Media coverage about SIEN stock has trended somewhat positive on Tuesday, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sientra earned a daily sentiment score of 0.18 on Accern's scale. They also assigned news coverage about the medical instruments supplier an impact score of 45.98 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Sientra's major shareholders?
Sientra's stock is owned by many different of institutional and retail investors. Top institutional shareholders include ABINGWORTH LLP (8.90%), Cannell Capital LLC (5.89%), BlackRock Inc. (3.90%), Bamco Inc. NY (2.99%), Senzar Asset Management LLC (2.69%) and Millennium Management LLC (2.26%). Company insiders that own Sientra stock include Jeffrey M Nugent, Patrick F Williams, R Scott Greer and Timothy Haines. View Institutional Ownership Trends for Sientra.
Which institutional investors are buying Sientra stock?
SIEN stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Cannell Capital LLC, Bamco Inc. NY, X Square Capital LLC, Senzar Asset Management LLC, Monarch Partners Asset Management LLC, Blair William & Co. IL and Quantum Capital Management. Company insiders that have bought Sientra stock in the last two years include Jeffrey M Nugent, Patrick F Williams, R Scott Greer and Timothy Haines. View Insider Buying and Selling for Sientra.
How do I buy shares of Sientra?
Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sientra's stock price today?
One share of SIEN stock can currently be purchased for approximately $20.20.
How big of a company is Sientra?
Sientra has a market capitalization of $589.87 million and generates $36.54 million in revenue each year. The medical instruments supplier earns $-64,020,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. Sientra employs 200 workers across the globe.
How can I contact Sientra?
Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected]
MarketBeat Community Rating for Sientra (SIEN)
MarketBeat's community ratings are surveys of what our community members think about Sientra and other stocks. Vote "Outperform" if you believe SIEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SIEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
